Roche sees positive results for new multiple sclerosis drug in late-stage trials

Please subscribe to IBJ to decode this article.

ih ttcarchaalren sp ettneth d'o d- shfisa po arogst rtlnasaseoo e lao ent er Snn r sptssterea ltioaliou mhxsetlinca empluir n oseyepetwoataias nrg ract iiwt eeerpho tmaoieagmur aicpamseayeReataSuphnswimuilt.dst c ir cthk mldnyfu tm

A D ub 2eirteoenroer’hsepnsvrtis rMh ripflegfbibyO Busco1toiSrncneg h,rdatun s rlno ainshecyt .h hrcasriv i -udocopr ksiacadd,sp aepmnl edlesPcRo n y ephrhe w fmuy inwescoaeosga lntfoiwbvlhs etnrIre,iaooiritwoilidGoiitdsnn aaue meg ei somoei,sdic ee-c RlahaRrs n tessbtpcolpsat%edik Pa sdode

e tacgooaoaipa1 s1im pottPmtn irt vs ese pmtf e ullellmse clUheiltinfrlktge o haiei iooiehPnSoem iwet Mi d eheoi tdnsnm y hA%ovn hnStssaellsoeatar,xr p0f d.tbpu,mia

ilddCehohb tp tncgtwessy v nle i io c nrnmeamsdst firmpoissssspaiarxrih,rieonahes etCneupvmht-wtli e cmla plmti tuotdeag er oi ge kh l socoodnpenicte slnsoolnoeopanceuretocm lt mi ldlerllpwfmg poa r ls tifri eyiogoste -enI eit miicaeois.em thiif,eene, lc i oprh eio gctistu fr

s t e r.ctsf Pnirr. noe0ng ale sSonh.i1orFaero rrrtidoeieaxlvne nineshsmDsuienpyeyiddo gee refRidnybbsvUp si p Sn1eOcruneiTdel doatdtrhpit acAuasi2oiPsbt adMenir 70 peu.itrmaerci entim

Sg en icvosaiesindets“vnrae r ehsRdcprMipitieFs atr g g l ne ebdb sonntcefr sonh aushcuonae o,p udleytacaonamce itSdenertmh,nfie e nea rr lbtbP rfdeakatcfeaiafslamln ct uhM ietc fm”agy rip iCnrytaienipaneaeeoeerdihinir tiyeruiiyriiestPnsfuPowehsobivis rtueag tlinePecvOl i ts e lonmoL.d i GM stprndirrtf r

rkt eonrtaop oicht ece to ts ga siublbmsbenn Ins9sehcl o.lrye ilaen 5 s O2 uwv1esphesdlyeaw eeute .aenthso iovalataotop2veo cme raroidpn8pdo eddaoviceltvtelnutr cetyfa sh fvrr ef0neTndi is eahe ala etie e bhu nhcaiIabiieernerhsfgkaivna tc r buuintemtO ait fd n nenIcnwneie aeo a ews,srp ili liatsPhpbep ejlitnrsts4wetdrb anuemrsft ia etharn tia y nate Iuu stncard,

hn t i ahetfpta-mtualcaa r .eeTnn haioeisysdul tt d mlfe eblttnaoslg siti l ndeippsybpttrenrniaoatesesrsoaolf tcsnaemuoi

aaanl bl mlplo p cnaoss h Rtu oail oihel r 4,hinifiianlsfiidecIatiperynnP a p8e soymvcgry fbwherho0toeno tlonRcI irohe eoa,Iii,aof sn Iheg tetiarDrtlmtmioecesrn.adsethb ps 0i uaf f iottwst eashrsu tra tl

i- raj/aRoi yrntda-th$leadsidi af erntae- sdy dleucctntt/taictwtethunnidrhudjivosiabgI sta l htopet- nfim-ea5nogs-wajulie pdeoya ro0ime/ s/leo a in1 f d.ateat 1-sx"c dogtHeo5pea5dsl:-o o /s ,ia>nRtd id5t<- sv irsenrdiselns"doob0e-oiu d paro.s-mb

-i dhIscpp0aadrd eleeima.vi nt"-adps.aatacp sril xTnv"s moiraeaeeh eoirepf-at.nga-em eecid at-i-,nopSp htls arUiehsp: c  tet -nea daatoonpnn stmssshir.wi ako eiagicrttui cit ssst / t ohtioced ecertrotpnfl